Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine (GEMCAD)
- Development stage
- Unknown
- Lead developer
- Grupo Cooperativo GEMCAD
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The autologous dendritic cell vaccine developed by the Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD) is an individualized cancer immunotherapy biologic designed for the treatment of mismatch repair-proficient (MSS) metastatic colorectal cancer. The vaccine is produced by harvesting a patient's own dendritic cells and loading them with tumor-associated antigens. Once administered via intradermal injection, these professional antigen-presenting cells activate the patient's immune system, specifically cytotoxic T cells, to recognize and eliminate colorectal cancer cells. In clinical development, notably the GEMCAD 1602 trial (NCT03152565), this vaccine is evaluated in combination with the anti-PD-L1 antibody avelumab to enhance anti-tumor efficacy in pre-treated patients.
- Other names
- ADC vaccineGEMCAD autologous dendritic cell vaccine
Beyond the preview
Go deeper on autologous dendritic cell vaccine (GEMCAD).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine (GEMCAD).